Engflag

ReoPro

Quick links to important sections

ReoPro

Selected form

ReoPro_TR

Method of action: Antithrombotic

Treatment option: Coronary Angioplasty, Accelerating Angina, Angina Pectoris

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of ReoPro

Property Description
Active Ingredient Abciximab
Form Solution for Intravenous Injection
Pharmacological Class Glycoprotein (GP) IIb/IIIa Inhibitor
General Purpose Clot Prevention / Platelet Blocker
Origin Biologic (Chimeric Fab Fragment)

What Type of Medicine is Abciximab (ReoPro)?

ReoPro is a high-potency antiplatelet agent belonging to the Glycoprotein (GP) IIb/IIIa inhibitor class, specifically designed to prevent the aggregation of platelets in the blood. The active ingredient is Abciximab, a specialized biologic medicine recognized for its rapid, potent action, a feature clinically recognized across multiple pharmacological studies. Abciximab's unique origin is key: it is structured as a chimeric Fab fragment derived from the 7E3 monoclonal antibody. This specific structure, combining mouse and human protein sequences, allows it to selectively target and bind to key receptors with high affinity, differentiating it from smaller, synthetic antiplatelet drugs. Abciximab is utilized for platelet inhibition in high-risk settings.

Abciximab Composition and Physical Form

Abciximab is the sole active ingredient in this single-active ingredient product and is provided as a sterile, non-pyrogenic solution intended solely for intravenous injection. As a high-molecular-weight biologic, its route of administration is strictly parenteral (outside the digestive tract); it cannot be taken orally. The medicine is supplied in a single-use vial, ensuring its sterility and stability prior to administration. The composition consists of the active Abciximab fragment suspended in a carefully buffered aqueous base, including essential stabilizers like sodium phosphate, sodium chloride, and polysorbate 80. This formulation ensures the solution maintains a suitable pH for safe delivery into the circulation.

What is the General Purpose of a Platelet Blocker?

The primary general purpose of Abciximab is to achieve strong platelet blockade, substantially reducing the blood's capacity to form new, unwanted clots. It operates by binding to the GP IIb/IIIa receptor on the platelet surface, effectively preventing adhesion molecules like fibrinogen from linking platelets together. This is the final common step in platelet aggregation. This highly specific action ensures a rapid and profound antiplatelet effect. For instance, this medicine is typically used during procedures intended to clear narrowed blood vessels. This pharmacological function helps to ensure continuous, smooth blood flow, positioning the medicine as a powerful therapeutic tool for immediate clot prevention.

Regulatory References

  1. Abciximab Injection Labeling (DailyMed)
  2. Platelet Aggregation Test (MedlinePlus)

What side effects are possible with ReoPro?

Possible side effects and safety information

The safety profile of Abciximab (ReoPro), a potent platelet aggregation inhibitor, is primarily defined by the risk of bleeding, which is a direct and expected consequence of its function. Official regulatory documents classify adverse events based on frequency and affected system-organ class.

Adverse Reaction Frequencies

Classification Examples of Adverse Reactions (Official Labeling)
Very Common (≥ 1/10) Bleeding events (minor and major)
Common (≥ 1/100 to <1/10) Thrombocytopenia, Hypotension, Bradycardia, Back pain, Nausea, Headache, Gastrointestinal haemorrhage
Uncommon (≥ 1/1,000 to <1/100) Intracranial haemorrhage
Rare (≥ 1/10,000 to <1/1,000) Anaphylactic reaction, Cardiac tamponade, Pulmonary haemorrhage

Serious adverse reactions explicitly documented include Major or Fatal Bleeding and Intracranial Haemorrhage. Other rare but serious events cited in regulatory sources are Anaphylactic Reaction and Adult Respiratory Distress Syndrome.

Safety Considerations

The most frequent and significant adverse event listed under Blood and Lymphatic System Disorders is Bleeding. Thrombocytopenia (low platelet count) is another common haematological effect; regulatory data indicates this risk is highest during the initial hours following administration. Older adults may be more susceptible to bleeding complications than younger patients, a note included in regulatory labeling.

Safety restrictions note that the bleeding risk is significantly increased when Abciximab is used concurrently with other agents that affect haemostasis.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation from government authorities indicates that no formal experience with adverse events specifically associated with overdosage has been reported in clinical trials. Overexposure to Abciximab is defined by an exaggerated antiplatelet effect, which leads directly to the primary documented clinical manifestation: severe hemorrhage (bleeding). Severe, life-threatening outcomes explicitly listed in the regulatory profile include intracranial bleeding and retroperitoneal bleeding.

Immediate medical attention must be sought for any signs of uncontrolled bleeding, such as bleeding that is difficult to stop with direct pressure, or for symptoms suggestive of internal hemorrhage.

The regulatory mandate is to immediately stop the ReoPro infusion, along with any concomitant heparin administration, upon the observation of serious bleeding or acute, profound thrombocytopenia (a severe drop in platelet count). No specific chemical antidote is known for Abciximab. Therefore, management is symptomatic and supportive. The primary supportive measure described in prescribing information is the procedural intervention of platelet transfusion, which is recommended to restore platelet function. Continuous platelet count monitoring is required due to the potential for severe blood abnormalities following overexposure.

Therapeutic Uses of ReoPro

What ReoPro Treats: Main Uses and Benefits

ReoPro is commonly used across domains involving cardiovascular care. This medication is relevant in clinical settings that involve acute or unstable symptom patterns, specifically used to help manage the risk of complications associated with certain heart conditions and procedures.

The medication is relevant in conditions involving episodic or fluctuating manifestations like severe chest pain, and is commonly used when short-term symptomatic assistance is needed during certain urgent procedures.

“It provides support that may generally assist with easing the overall symptom burden during periods of heightened cardiac discomfort.”

Quick Fact: Supportive Management for Acute Symptoms

This supportive care helps address symptom clusters that may become intense or disruptive and contributes to improved comfort during periods of heightened symptoms by assisting with managing the risk of symptomatic relapse following the procedure. It is applied when supportive symptom management is appropriate to support functional stability when symptoms interfere with routine activities.

Regulatory References

  1. Health Canada Product Monograph

Eligibility and Restrictions for Use

Who Can and Cannot Use ReoPro?

The population eligibility for ReoPro (Abciximab) is strictly defined by regulatory bodies like the FDA and EMA, primarily due to the potent risk of bleeding associated with this antiplatelet medicine. Eligibility is generally limited to adult patients receiving or planning to receive percutaneous coronary intervention (PCI).

Contraindicated Populations (Absolute Ban)

ReoPro must not be administered to individuals with specific conditions that increase the risk of hemorrhage. Contraindications include active internal bleeding, known hypersensitivity to Abciximab or murine antibodies, and a history of a cerebrovascular accident (CVA) within the last two years or any CVA resulting in a residual neurological deficit. The medicine is also prohibited for patients with a known bleeding diathesis, recent significant gastrointestinal or genitourinary bleeding (within six weeks), or recent use of oral anticoagulants (within seven days) unless blood clotting parameters are verified.

Special Population Restrictions

Population Group Regulatory Status
Pediatric Patients (< 18) Safety and effectiveness have not been established.
Older Adults (> 65) Use with caution; increased sensitivity and higher risk of bleeding complications are noted.
Pregnant Women Conditional Use (Category C); only if potential benefit justifies the risk to the fetus.
Lactating Women Conditional Use; caution is recommended as excretion into human milk is unknown.

Eligibility criteria are not established for patients with renal or hepatic impairment.

What should I know about interactions with other medicines?

ReoPro (Abciximab) is an antiplatelet agent. Due to its mechanism of inhibiting platelet function, its primary interaction concern is a potentially increased risk of bleeding when combined with other medicines that affect blood clotting or platelet activity. This effect is considered pharmacodynamic, meaning the combination of products leads to an additive effect on hemostasis.

Documented Interacting Medicinal Product Categories

Category Concern Notes
Anticoagulants (e.g., Heparin, Oral Anticoagulants) Increased risk of bleeding Combination increases anti-clotting effects.
Other Antiplatelet Agents (e.g., Aspirin, Clopidogrel, Ticlopidine, Dipyridamole) Increased risk of bleeding Combination increases platelet inhibition.
Thrombolytics (e.g., Alteplase) Increased risk of major bleeding Risk/benefit must be carefully weighed by a healthcare provider.
Dextran Increased risk of bleeding Additive effect on hemostasis.
Non-steroidal Anti-inflammatory Drugs (NSAIDs) Increased risk of bleeding Affects platelet function.

It is important to note that ReoPro is intended for use with acetylsalicylic acid (Aspirin) and Heparin, and its efficacy and safety have been established only within this concurrent therapy regimen. Therefore, its use is contingent on careful monitoring and management of all co-administered agents affecting the blood's ability to clot.

Mechanism of Action

Blocking the Final Pathway of Platelet Aggregation

ReoPro (Abciximab) functions by acting as a molecular antagonist of the Glycoprotein (GP) IIb/IIIa receptor (alphaIIbbeta3 integrin) on the platelet surface. This receptor mediates the final, common step in platelet aggregation. The drug's Fab fragment structure binds to the receptor, physically preventing adhesion molecules, primarily fibrinogen and von Willebrand factor, from creating cross-links between platelets. This action inhibits platelet aggregation regardless of the initial activating stimulus, resulting in a systemic mathbfantithrombotic state.

Sustained Adhesion Control and Mechanistic Requirements

Abciximab also binds to the Vitronectin receptor and the Mac-1 receptor on vascular cells and leukocytes, modulating their adhesive properties. The mechanism is threshold-dependent, requiring at least 80% receptor occupancy to functionally impair mathbfhemostasis. Because the drug remains bound for a prolonged period, mathbfinhibition of platelet function persists for 24 to 48 hours after infusion stops, reflecting the molecule's slow dissociation kinetics. The mechanism is solely preventative and mathbfdoes not dissolve existing clots.

Dosage and Administration Information

How to Use ReoPro (Abciximab) — Administration Guidelines

ReoPro is administered exclusively via intravenous (IV) injection followed by a prolonged continuous IV infusion in a hospital setting with specialist care available. Its use is defined as an adjunct to aspirin and heparin therapies during and after coronary procedures.

Dosing and Timing

The administration schedule is precisely timed relative to the procedure, typically Percutaneous Coronary Intervention (PCI):

Administration Component Standard PCI Regimen Unstable Angina Regimen
Bolus Dose 0.25 mg/kg body weight 0.25 mg/kg body weight
Timing (Bolus) 10 to 60 minutes before PCI start Up to 24 hours prior to PCI
Infusion Dose 0.125 mcg/kg/min (max 10 mcg/min) 10 mcg/min (fixed rate)
Infusion Duration 12 hours following PCI 18 to 24 hours, concluding 1 hour after PCI

Preparation and Procedural Rules

ReoPro is supplied as a sterile solution that requires specific preparation before administration. The dose must be diluted in either 0.9% saline or 5% dextrose for infusion. Importantly, both the bolus dose and the continuous infusion must be filtered using a sterile, low protein-binding filter (0.2 or 5 micron for the bolus; 0.2 or 0.22 micron for the infusion) to remove particulates prior to delivery.

The medication should be administered via a separate intravenous line whenever feasible. Use in pediatric patients (under 18 years) requires specific medical determination and is not covered by standard adult dosing protocols. If the interventional procedure (PCI) is unsuccessful, the continuous infusion of ReoPro must be stopped.

Recent Clinical Evidence

ReoPro: Recent Clinical Evidence

Abciximab (ReoPro) is a glycoprotein IIb/IIIa inhibitor often used as an adjunct to percutaneous coronary intervention (PCI). Clinical research, including large, randomized trials such as the EPIC, EPILOG, and CAPTURE studies, has evaluated the compound's effect in reducing adverse cardiac events following these procedures.

Key findings from these initial studies established that abciximab, when used with standard antithrombotic therapy (aspirin and heparin), was associated with a reduction in the combined endpoint of death, myocardial infarction (MI), or urgent revascularization within 30 days after PCI.

Outcomes in Specific Patient Groups

Subsequent clinical investigation has focused on defining the benefits in various patient subgroups, particularly as newer antiplatelet agents have been introduced.

Patient Population Key Research Findings (Summary)
Diabetic Patients Meta-analyses have explored the potential for a sustained reduction in the risk of death or re-infarction over long-term follow-up (up to 3 years) in patients with diabetes undergoing primary PCI.
Readministration Studies examining the readministration of abciximab during subsequent PCI procedures reported clinical success rates consistent with first-time use. Thrombocytopenia, however, occurred in a minority of patients, with a need for systematic monitoring.
High Clopidogrel Loading Several trials have investigated whether abciximab provides additional benefit when patients are pre-treated with high loading doses of clopidogrel, with some studies suggesting no measurable added benefit in low-to-intermediate-risk patients.

Overall, the body of evidence continues to focus on the compound's safety profile, with bleeding complications and thrombocytopenia (low platelet count) being the most commonly observed adverse events in clinical trials.

Frequently Asked Questions (FAQ)

Common questions about ReoPro (FAQ)

Q: How soon after stopping the infusion does the drug's effect wear off?

The antiplatelet effect of ReoPro gradually decreases after the continuous infusion is stopped. In clinical studies, the return of platelet function to near-normal levels was observed within 12 to 24 hours after the infusion ended for most patients. This range represents the time it took for bleeding time to return to pre-specified levels, according to official product information.

Q: Can ReoPro be used to dissolve an existing blood clot?

No, ReoPro (Abciximab) is not classified as a thrombolytic (clot-dissolving) medicine. Its pharmacological purpose is to inhibit platelet aggregation, which helps prevent the formation of new blood clots during and after certain heart procedures. It is not designed to break down clots that have already formed.

Q: Does the body develop antibodies against Abciximab?

Because Abciximab is a chimeric protein (derived from mouse and human components), there is a potential for the human body to develop antibodies against it. Official labeling notes that these Human Anti-Chimeric Antibodies (HACA) were detected in a small percentage of patients during clinical trials. This is an immune response that may occur with biologic medicines.

Q: Does ReoPro interact with grapefruit or other foods?

The official regulatory documents list known drug-drug interactions, primarily with other medicines that affect blood clotting. However, the product labeling does not specifically include any known interactions with foods, beverages such as grapefruit, or alcohol.

How should ReoPro be stored and disposed of?

How to Store and Dispose of ReoPro (Abciximab)

ReoPro must be stored under specific environmental and temperature conditions as required by its official labeling to maintain its stability.

Storage Requirements

  • Mandatory Temperature: The unopened vial must be stored in a refrigerator at 2 C to 8 C (36 F to 46 F).
  • Freezing and Light: Do not freeze the product; if frozen, it must be discarded. Vials must be stored in their original carton to be protected from light.
  • Child Safety: Keep the medicine out of the sight and reach of children.

Handling and Disposal

  • In-Use Stability: After dilution, the solution is chemically stable for 12 hours at room temperature or refrigerated, but immediate use is recommended (microbiologically).
  • Discarding Unused Product: Any unused portion of ReoPro remaining in the vial or infusion solution must be discarded at the end of the infusion period.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagArgentina

flagAustralia

flagAustria

flagBelgium

flagBrazil

flagBulgaria

flagCanada

flagChile

flagCzech Republic

flagFinland

flagFrance

flagGermany

flagGreece

flagHong Kong

flagIceland

flagIreland

flagItaly

flagMalaysia

flagMexico

flagNetherlands

flagNew Zealand

flagNorway

flagPoland

flagPortugal

flagRussia

flagSouth Africa

flagSpain

flagSweden

flagSwitzerland

flagTaiwan

flagUnited Kingdom

flagUSA

Equivalent of ReoPro found in:

A-Z Index: